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OBJECTIVES: The objective of this early postlaunch analysis
was to examine medication persistence among women °Y´45
years and newly prescribed monthly or weekly bisphosphonate
(BP) therapy at 9 months. METHODS: The i3 Innovus admin-
istrative claims database was used to retrospectively identify
female patients who ﬁlled a new prescription for a weekly BP
(risedronate or alendronate) or monthly ibandronate starting in
April 2005. Medication persistence was deﬁned as having no
reﬁll gaps exceeding grace periods of 30 (weekly BPs) and 45
days (monthly BPs). Cox proportional hazard analysis was used
to control for the effects of potential confounding factors includ-
ing age, co-pay, and co-morbidities. RESULTS: This analysis
included 967 women prescribed monthly ibandronate and 8662
women prescribed weekly BPs. At 9-months, the median number
of days until discontinuation was 236 days for monthly and 141
days for weekly (p < 0.0001). Signiﬁcantly more patients receiv-
ing monthly ibandronate were persistent compared to patients
receiving weekly BPs (48% vs 35%, P < 0.0001). After adjust-
ing for potential confounding factors, monthly users overall were
38.0% more likely to persist with therapy versus weekly users
(hazard ratio = 0.620, 95% CI 0.563–0.683, P < 0.0001). CON-
CLUSION: The 9-month results of this analysis indicate that
more women on monthly therapy are persistent than women on
weekly bisphosphonates. This early ﬁnding suggests enhanced
long-term persistence with ibandronate monthly therapy, with
the potential for improved clinical outcomes. Follow-up of this
cohort is ongoing.
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OBJECTIVES: Data from health care databases are used to
determine patient persistence with bisphosphonates in a real-
world setting. The observational nature of retrospective database
studies removes a source of potential inﬂuence on patient behav-
ior. The objective of this analysis is to evaluate 9-month persis-
tence among patients receiving monthly ibandronate versus
weekly bisphosphonates. METHODS: De-identiﬁed patient data
were collected from the HealthCore managed care claims data-
base, which represents over 17.5 million covered lives. Eligible
women were °Y´45 years and ﬁlled a new prescription for
monthly ibandronate or weekly alendronate or risedronate start-
ing April 1, 2005. Persistence was evaluated based on a gap in
coverage of 30 days for weekly bisphosphonates; a 45-day gap
was analyzed for monthly ibandronate due to its 3-week dosing
window. Cox proportional hazard models were used to analyze
persistence and controlled for potential confounders such as age,
patient co-pay, and comorbidities. RESULTS: A total of 4548
women were included (213 receiving monthly ibandronate and
4335 receiving weekly therapy). The median number of days
until discontinuation for monthly was 145 days and for weekly
was 115 days (p = 0.0032). At 9 months, signiﬁcantly more
patients receiving monthly ibandronate (41%) were persistent
compared to patients receiving weekly BPs (33%) (P = 0.003).
After adjusting for age, co-pay, comorbidities, and prescriptions
with greater than a 30-day supply, monthly users were 31% less
likely to discontinue therapy compared with weekly users at 9
months (P < 0.0001). CONCLUSION: Persistence during the
initial 9 months after launch of ibandronate was higher for iban-
dronate monthly BP therapy than weekly BP therapy. Longer
follow-up of this cohort is ongoing.
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OBJECTIVES: For survivors of traumatic injury, critical care ser-
vices are often required, followed by long-term recovery as
patients overcome or adapt to the effects of their injury on phys-
ical function (Holtslag, 2006). Recently, increased attention has
been focused on the use of patient reported outcome (PRO)
assessments to evaluate functional outcomes in this population.
In order to appraise current validation evidence for the use of a
simple-to-administer PRO (Physical Function (PF) Scale of the
Medical Outcomes Study Short-Form (SF-36) health survey), a
literature review was completed. METHODS: Comprehensive
literature review (including a review of articles identiﬁed from
previous work with trauma patient populations and with the SF-
36 as well as a comprehensive search of PUBMED & EMBASE,
2000–2006 for articles that used PRO measures to assess recov-
ery in trauma patients); 92 articles were reviewed. RESULTS:
Ten studies presented psychometric data for the SF-36 in trauma
patients (number of trauma patients included in these studies
ranged from 64–1197). PF Scale properties were as follows:
Internal consistency reliability: Alpha = 0.93 (multiple trauma
patients; Statz, 2002). Discriminant validity: The PF Scale 
discriminated between patients with different injury types
(Michaels, 2001). Trauma patients had signiﬁcantly lower PF
scores (p < 0.001) than control patients with no disability
(Findler, 2001) and US norms at various time points (up to 27
months) post-trauma (Brennenman, 1995; Holtslag, 2006;
Hoogendoorn, 2001). Concurrent validity: PF scores were sig-
niﬁcantly related to those on the Sickness Impact Proﬁle (Holt-
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slag, 2006), neurocognitive functioning (COG scale) (Macken-
zie, 2002), and Beck Depression Inventory (Findler, 2001).
CONCLUSION: There is evidence to suggest that the PF Scale
of the SF-36 is reliable, as measured by internal consistency, and
valid, as measured by discriminant and concurrent validity.
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OBJECTIVES: New BA offer more therapeutic options to
control psoriasis symptoms but add to the already considerable
cost of managing psoriasis. Expert panels have published guide-
lines for the use of BA although few of them considered the treat-
ment options cost-effectiveness. The Brazilian expert guidelines,
however, considered. We present a Brazilian cost effectiveness
model based on micro-simulation. METHODS: Our cost effec-
tiveness model simulates the real-life Brazilian treatment
sequence (acitretin, methotrexate, cyclosporine, BA) for 1000
patients based on the average time of use of each drug (10.74,
6.56, 24.00, and 30.00 months, respectively). Three different
BA, adalimumab, eternacept and inﬂiximab, were analyzed. Cost
effectiveness was calculated in terms of the number of patients
that achieve PASI 75 response with each BA. The base case was
a moderate-to-severe psoriasis patient, with at least 10% BSA
affected, PASI score of at least 12, without infection in the lesions
and eligible for systemic therapy. Time of use of each drug in
Brazil came from a previous Brazilian study and the PASI score
from major studies with each drug from the medical literature.
The local disease management and costs were based on a Delphi
panel according to the private health care perspective. Outcomes
were discounted at 3% annually. RESULTS: In order that all
patients pass all the four treatment lines it took an average time
of 71.3 months; the Brazilian treatment sequence added to fort-
nightly adalimumab, weekly adalimumab, inﬂiximab and eter-
nacept, respectively, generated 529, 799, 879 and 490 patients
achieving PASI 75 and also, respectively, generated R$
129,071,880.38, R$ 257,708,724.48, R$ 132,251,142.76, R$
342,274,532.45 total costs. CONCLUSION: The Brazilian
treatment sequence added to inﬂiximab is a dominant alterna-
tive in relation to that added to weekly adalimumab and eter-
nacept. It also has an acceptable cost-effectiveness ratio in Brazil
in relation to fortnightly adalimumab (R$9092.70).
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs associated with patients diagnosed
with atopic dermatitis (AD) from an employer-payer perspective.
METHODS: A de-identiﬁed claims database consisting of 5.1
million covered lives from 31 Fortune 500 self-insured employ-
ers over the period 1998–2005 was used. Each AD patient was
matched with three controls based on age and gender. The
average monthly direct health care costs (i.e., medical & phar-
maceutical costs) were computed for the respective groups. For
the subset of patients who were active employees, the indirect
costs of lost work time were calculated for each group, as mea-
sured by employer disability payments and sick leave time 
multiplied by the employee’s wage. In addition, a multivariate
two-part regression was used to isolate the cost increase attrib-
utable to AD by controlling for age, gender, year, comorbidities,
and organ transplantation. RESULTS: The univariate analysis
showed that the AD patients (N = 13,749) were associated with
higher medical and pharmacy costs than the control group (N =
41,247) by an average of $47 and $42 per person per month,
respectively (medical: $270 vs. $223, p < 0.003; pharmacy: $80
vs. $38, p < 0.0001), bringing the total increase in health care
costs to $88 per person per month ($349 vs. $261, p < 0.0001).
In the subset of active employees, the AD group (N = 1588) was
associated with higher indirect work loss costs of $64 per person
per month ($148 vs. $85, p < 0.0001) than the control group (N
= 3900). For each cost category, a statistically signiﬁcant cost
increase for AD patients was conﬁrmed through the multivari-
ate analysis (adjusted incremental direct cost = $52, p < 0.0001;
adjusted incremental indirect cost = $31, p < 0.0001). CON-
CLUSION: AD was associated with a statistically signiﬁcant
increase in health care and work loss costs. The multivariate
analysis indicated that the total direct and indirect cost increase
was approximately $83 per person per month.
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OBJECTIVES: To determine the incremental direct health care
and indirect work loss costs experienced by employer-payers for
patients diagnosed with seborrheic dermatitis (SD). METHODS:
A de-identiﬁed claims database consisting of 5.1 million covered
lives from 31 Fortune 500 self-insured employers over the period
1998–2005 was used. Each SD patient was matched with three
controls based on age and gender. The average monthly direct
health care costs (i.e., medical & pharmaceutical costs) were
computed for the respective groups. For the subset of patients
who were active employees, the indirect costs of lost work time
were calculated for each group, as measured by employer dis-
ability payments and sick leave time multiplied by the employee’s
wage. In addition, a multivariate two-part regression was used
to isolate the cost increase attributable to SD by controlling for
age, gender, year, comorbidities, and organ transplantation.
RESULTS: The univariate analysis showed that the SD patients
(N = 6860) were associated with higher medical and pharmacy
costs than the control group (N = 20,580) by an average of $136
and $62 per person per month, respectively (medical: $412 vs.
$277, p < 0.0001; pharmacy: $139 vs. $76, p < 0.0001), bring-
ing the total increase in health care costs to $198 per person per
month ($551 vs. $353, p < 0.0001). In the subset of active
employees, the SD group (N = 1666) was associated with a
higher indirect work loss cost of $50 per person per month ($132
vs. $82, p < 0.0001) than the control group (N = 4103). For each
cost category, a statistically signiﬁcant cost increase for SD
patients was conﬁrmed through the multivariate analysis
(adjusted incremental direct cost = $62, p = 0.005; adjusted
incremental indirect cost = $44, p = 0.042). CONCLUSIONS:
SD was associated with a statistically signiﬁcant increase in
health care and work loss costs. The multivariate analysis indi-
